Postpartum thyroiditis in women with hypothyroidism antedating pregnancy?
In women with hypothyroidism, levothyroxine (LT) requirements after delivery are assumed to return to prepregnancy values. The occasional observation of discordances prompted this study. Forty-one women (31 receiving LT replacement therapy and 10 receiving suppressive therapy for thyroid carcinoma) were followed during the first year after delivery. A control group of 31 nonpregnant women with hypothyroidism (n = 21) or thyroid carcinoma (n = 10) were also followed during a similar period. Twenty-three patients of 41 (56.1%) had discordant requirements at follow-up after delivery vs. 3 of 31 in the control group (9.7%; P < 0.001). The patterns of discordance in the postdelivery group were hyperthyroidism in 12, increase in LT dose in 5, hyper- and hypothyroidism in 5, and recurrence of Graves' disease in 1 women. Those in the control group were increase in LT dose, hyperthyroidism, and hypo- and hyperthyroidism. The rate of patients with discordant prepregnancy-postpartum LT doses was higher in the noncarcinoma subgroup (67.7% vs. 20.0%; P < 0.01), whereas in the control group, both subgroups displayed a similar rate of discordance (9.5% vs. 10%; P = NS). In conclusion, this study documents that women with hypothyroidism antedating pregnancy display changes in LT requirements in the first year after delivery that suggest postpartum thyroiditis.
Caixàs
A
A
Servei d'Endocrinologia i Nutrició, Hospital de Sant Pau, Barcelona, Spain.
Albareda
M
M
García-Patterson
A
A
Rodríguez-Espinosa
J
J
de Leiva
A
A
Corcoy
R
R
D001327:Autoimmune Diseases / Q000188:drug therapy; D005260:Female; D006111:Graves Disease / Q000188:drug therapy; D006801:Humans; D007037:Hypothyroidism / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016015:Logistic Models; D011247:Pregnancy; D011248:Pregnancy Complications; D011644:Puerperal Disorders / Q000150:complications*; D013964:Thyroid Neoplasms / Q000188:drug therapy; D013966:Thyroiditis / Q000097:blood / Q000150:complications*; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use
D013972:Thyrotropin; D013974:Thyroxine